

FendX is an innovative nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens. FendX is building a robust patent portfolio based on the repelling properties of its nanotechnology. Our lead product under development, REPELWRAP™, is a protective surface coating that, due to its repelling properties, prevents adhesion of pathogens and reduces their transmission on surfaces prone to contamination.

Investment Highlights

- ✓ Award-winning, patent-pending nanotechnology
- ✓ Building a robust patent portfolio
- ✓ Numerous potential applications in healthcare and other industries
- ✓ Pipeline of products under development including REPELWRAP™ line extensions, coating of catheters and additional formulations
- ✓ Unique nanotechnology that repels bacteria, viruses and blood keeping surfaces safe from contamination
- ✓ REPELWRAP™ ready for scale-up with a path to commercialization
- ✓ Experienced management team with a proven track record

Share Structure

At March 20, 2023

Common Stock ¹	: 51,913,453
Stock Options	: 2,775,000
Restricted Share Units	: 150,000
Warrants	: 16,800,627
Bonus shares ²	: 4,150,000
Fully-diluted	: 75,789,080

¹ 35,649,666 shares subject to escrow/ voluntary pooling restrictions at listing.

² Shares issuable upon satisfaction of certain development milestones.

Management

Dr. Carolyn Myers MBA, PhD
President, Chief Executive Officer, Director

Andrea Mulder BPHE, EMBA
Chief Operating Officer

Rose Zanic CPA, CA
Chief Financial Officer


Board of Directors

Dr. Carolyn Myers MBA, PhD
President, Chief Executive Officer, Director

Stephen Randall CPA, CGA
Independent Board Member
& Audit Committee Chair

Pierre Soulard B.C.L., LLB, LLM
Independent Board Member

Company Objectives



For more information, contact: Jennifer Smith

✉ investor@fendxtech.com | ☎ (902) 229-7265

Disclaimer: This corporate profile contains certain forward-looking statements, including with respect to: the plans of FendX Technologies Inc. (the "Company"); the Company's REPELWRAP™ product and the expected timing and completion of our near term objectives. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and they involve a number of risks and uncertainties, including the risk factors set forth in the Company's final prospectus dated January 31, 2023 under the heading "Risk Factors", available at www.sedar.com. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update any forward-looking statements except as required by applicable securities legislation.